Program
ruzinurad
Also written as “SHR4640”, “SHR4640 tablet” and “SHR4640 dose1”.
Its studies are mostly in Hyperuricemia · Gout, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Aug 6, 201920 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 201 open or running | phase 3since Aug 6, 2019 | Apr 27, 2016 | Jul 2027phase 2 · NCT07362355 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Apr 27, 2016.
- Jun 27, 2017Phase 1 study in GoutNCT03211403 · 24 enrolled · Australia
- Aug 6, 2019Phase 3 study in GoutNCT04052932 · 594 enrolled · China
- Nov 4, 2019Phase 1 study in HyperuricemiaNCT04157959 · 28 enrolled · China
- Nov 26, 2019Phase 2 study in HyperuricemiaNCT04180982 · 84 enrolled
- Jan 20, 2020Phase 1 study in Healthy Adult Male VolunteersNCT04260373 · 6 enrolled · China
- Mar 10, 2020Phase 1 study in Hepatic ImpairmentNCT04305392 · 24 enrolled · China
- Sep 27, 2020Phase 1 study in HyperuricemiaNCT04586803 · 24 enrolled
- Nov 3, 2020Phase 1 study in Healthy SubjectsNCT04620408 · 14 enrolled
- Apr 19, 2021Phase 1 study in Healthy Male SubjectsNCT04850638 · 18 enrolled · China
- Jul 7, 2021Phase 3 study in GoutNCT04956432 · 779 enrolled · China
- Aug 22, 2022Phase 2 study in HyperuricemiaNCT05513976 · 129 enrolled
- Jul 13, 2023Phase 1 study in HyperuricemiaNCT05954169 · 16 enrolled · China
- Dec 5, 20232 phase 1 studiesNCT06168929, NCT06196580
- Jan 15, 2026Phase 2 study in HyperuricemiaNCT07362355 · 340 planned · China
Ahead
- Jul 2027Primary completion: phase 2 study in HyperuricemiaNCT07362355
TargetBeta
SLC22A12 →read by rule
“Solute carrier family 22 member 12 inhibitor”ChEMBL 37, by rule
Other programs on SLC22A12
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| dotinuradrule | fuji-yakuhin-co-ltd | phase 3 | 22 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07362355Hyperuricemia · China | 2 | Recruiting | Jul 2027 | 340 |
| NCT06196580Gout · China | 1 | Completed | Feb 16, 2024 | 24 |
| NCT06168929Hyperuricemia · China | 1 | Completed | Jan 13, 2024 | 34 |
| NCT05954169Hyperuricemia · China | 1 | Completed | Jul 1, 2024 | 16 |
| NCT05513976Hyperuricemia | 2 | UNKNOWN | May 30, 2023 | 129 |
| NCT04956432Gout · China | 3 | Completed | Dec 13, 2023 | 779 |
| NCT04850638Healthy Male Subjects · China | 1 | Completed | Sep 5, 2021 | 18 |
| NCT04620408Healthy Subjects | 1 | UNKNOWN | Jan 2021 | 14 |
| NCT04586803Hyperuricemia | 1 | UNKNOWN | Nov 2020 | 24 |
| NCT04305392Hepatic Impairment · China | 1 | UNKNOWN | Dec 2022 | 24 |
| NCT04260373Healthy Adult Male Volunteers · China | 1 | Completed | Apr 3, 2020 | 6 |
| NCT04180982Hyperuricemia | 2 | UNKNOWN | Jul 30, 2020 | 84 |
| NCT04157959Hyperuricemia · China | 1 | UNKNOWN | Jun 1, 2020 | 28 |
| NCT04052932Gout · China | 3 | Completed | Jul 14, 2021 | 594 |
| NCT03211403Gout · Australia | 1 | Completed | Feb 15, 2018 | 24 |
| NCT03185793Hyperuricemia · China | 2 | Completed | Jul 20, 2018 | 198 |
| NCT03131583Gout · China | 1 | Completed | Jan 29, 2018 | 15 |
| NCT03015948Gout · Australia | 1 | Completed | Nov 23, 2016 | 40 |
| NCT02890966Gout · China | 1 | Completed | Feb 2017 | 48 |
| NCT02815839Gout · China | 1 | Completed | Feb 2017 | 50 |
How it is read
Names in the registry
- “SHR4640”, 15 entries
- “SHR4640 tablet”, 2 entries
- “SHR4640 dose1”, 2 entries
- “SHR4640 ;Febuxostat”, 1 entry
- “SHR4640 ; Febuxostat”, 1 entry
Codes read as this program: SHR4640.
Conditions, from the studies’ own filings
- Hyperuricemia, 8 studies
- Gout, 8 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.